Advertisement
Advertisement
IMCR
Immunocore Holdings plc - ADR
30.48
USDSponsored
+0.20
+0.64%
Mar 26, 15:59 UTC -4
Closed
After-Market
30.55
+0.08
+0.26%
IMCR Earnings Reports
Positive Surprise Ratio
IMCR beat 12 of 21 last estimates.
57%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$109.80M
/-$0.27
Implied change from Q4 25 (Revenue/ EPS)
+5.09%
/-55.00%
Implied change from Q1 25 (Revenue/ EPS)
+16.96%
/-370.00%
Immunocore Holdings plc - ADR earnings per share and revenue
On Feb 25, 2026, IMCR reported earnings of -0.60 USD per share (EPS) for Q4 25, missing the estimate of -0.24 USD, resulting in a -141.84% surprise. Revenue reached 104.48 million, compared to an expected 109.46 million, with a -4.55% difference. The market reacted with a -4.51% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 109.80 million USD, implying an decrease of -55.00% EPS, and increase of 5.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Immunocore Holdings plc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Immunocore Holdings plc - ADR reported EPS of -$0.60, missing estimates by -141.84%, and revenue of $104.48M, -4.55% below expectations.
How did the market react to Immunocore Holdings plc - ADR's Q4 2025 earnings?
The stock price moved down -4.51%, changed from $33.68 before the earnings release to $32.16 the day after.
When is Immunocore Holdings plc - ADR expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Immunocore Holdings plc - ADR's next earnings report?
Based on 12
analysts, Immunocore Holdings plc - ADR is expected to report EPS of -$0.27 and revenue of $109.80M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement